Tamoxifen for hepatocellular carcinoma

Area of Science:

• Hepatocellular carcinoma (HCC) research
• Clinical trial methodology
• Cancer treatment efficacy

Background:

• Hepatocellular carcinoma (primary liver cancer) is a leading cause of cancer mortality worldwide.
• Survival rates for advanced HCC remain poor.
• Previous trials on tamoxifen for HCC have yielded conflicting results.

Purpose of the Study:

• To systematically review the literature on tamoxifen's effects in advanced hepatocellular carcinoma.
• To assess tamoxifen's impact on overall survival, quality of life, tumor response, and toxicity.
• To provide evidence-based recommendations for tamoxifen use in HCC.

Main Methods:

• Systematic literature search of multiple databases (Cochrane, MEDLINE) and trial registers.
• Inclusion of all randomized clinical trials comparing tamoxifen to control treatments.
• Meta-analysis using a fixed-effect model to derive hazard ratios for overall survival.

Main Results:

• Ten randomized trials involving 1709 patients were analyzed.
• Tamoxifen showed no significant effect on overall survival compared to placebo/no intervention (HR 1.05, P=0.4).
• Tamoxifen was associated with adverse effects, and subgroup analyses suggested potential increased mortality in higher-quality trials.

Conclusions:

• Current data do not support the use of tamoxifen for treating hepatocellular carcinoma.
• Further research investigating tamoxifen in HCC is not warranted based on existing evidence.
• Clinical practice should consider these findings when managing advanced HCC.